Initial choice and switching of P2Y12 inhibitors among patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI)

被引：0
|
作者：
Wang, Yehua [1 ]
Brown, Joshua [2 ]
Cavallari, Larisa [3 ]
Winterstein, Almut [1 ]
机构：
[1] Univ Florida, Gainesville, FL 32611 USA
[2] Univ Florida, Coll Pharm, Ctr Drug Evaluat & Safety, Dept Pharmaceut Outcomes & Policy, Gainesville, FL 32610 USA
[3] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
386
引用
下载
收藏
页码：170 / 170
页数：1
相关论文
共 50 条
  • [41] Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
    Christodoulidis, Georgios
    Baber, Usman
    Mehran, Roxana
    CURRENT OPINION IN CARDIOLOGY, 2014, 29 (04) : 301 - 306
  • [42] Effect of new p2y12 inhibitors in patients with chronic kidney disease after an acute coronary syndrome
    Deharo, P.
    Pankert, M.
    Bonnet, G.
    Quilici, J.
    Bonnet, J. L.
    Cuisset, T.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1163 - 1163
  • [43] ARCANGELO: an observational, prospective study with acute coronary syndrome patients undergoing percutaneous coronary intervention who receive cangrelor transitioning to oral P2Y12 inhibitors
    De Luca, L.
    Calabro, P.
    Capranzano, P.
    Musumeci, G.
    Di Mario, C.
    Bolognese, L.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [44] De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention
    Kupka, Danny
    Sibbing, Dirk
    KOREAN CIRCULATION JOURNAL, 2018, 48 (10) : 863 - 872
  • [45] Spoiled for Choice: P2Y12 Receptor Inhibition in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
    Sibbing, Dirk
    Massberg, Steffen
    Rizas, Konstantinos D.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2024, 17 (11)
  • [46] P2Y12 Platelet Receptors: Importance in Percutaneous Coronary Intervention
    de Andrade Falcao, Felipe Jose
    Carvalho, Leonardo
    Chan, Mark
    Rodrigues Alves, Claudia Maria
    Camargo Carvalho, Antonio Carlos
    Caixeta, Adriano Mendes
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2013, 101 (03) : 277 - 282
  • [47] Dual antithrombotic therapy with oral anticoagulant and P2Y12 inhibitors in patients with atrial fibrillation after percutaneous coronary intervention
    Kitahara, Hideki
    Yamashita, Daichi
    Sato, Takanori
    Suzuki, Sakuramaru
    Hiraga, Takashi
    Yamazaki, Tatsuro
    Matsumoto, Tadahiro
    Kobayashi, Takahiro
    Ohno, Yuji
    Harada, Junya
    Fukushima, Kenichi
    Asano, Tatsuhiko
    Ishio, Naoki
    Uchiyama, Raita
    Miyahara, Hirofumi
    Okino, Shinichi
    Sano, Masanori
    Kuriyama, Nehiro
    Yamamoto, Masashi
    Sakamoto, Naoya
    Kanda, Junji
    Kobayashi, Yoshio
    JOURNAL OF CARDIOLOGY, 2023, 82 (03) : 207 - 214
  • [48] The influence of P2Y12 gene polymorphisms on clopidogrel therapy in patients after percutaneous coronary intervention
    Pawlak, Kornel
    Danielak, Dorota
    Burchardt, Pawel
    Kruszyna, Lukasz
    Karazniewicz-Lada, Marta
    FUTURE CARDIOLOGY, 2024,
  • [49] Evaluation of P2Y12 adenosine diphosphate receptor antagonists in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    Yuen, Meggie
    Abraham, Teena
    Brener, Sorin
    Oh, Erin
    Eldabie, Helen
    Balmir, Eric
    Cooperstein, Kathryn
    PHARMACOTHERAPY, 2012, 32 (10): : E274 - E274
  • [50] P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
    Feng, Wen-Han
    Chang, Yong-Chieh
    Lin, Yi-Hsiung
    Chen, Hsiao-Ling
    Chen, Chun-Yin
    Lin, Tsung-Han
    Lin, Tzu-Chieh
    Chang, Ching-Tang
    Kuo, Hsuan-Fu
    Chang, Hsiu-Mei
    Chu, Chih-Sheng
    PHARMACEUTICALS, 2023, 16 (02)
12345